Kono K, Nakata K, Muro T, Furukawa R, Ogino T, Kusumoto Y, Ishii N, Munehisa T, Koji T, Nagataki S
Oncodev Biol Med. 1983;4(6):C87-94.
Studies have been undertaken to clarify the localizing properties of radioactively labeled antibody to AFP using ascitic hepatoma cells which produce AFP. In the in vitro studies, radioantibodies to AFP were incorporated into the AFP-producing cells, even though excess antigen existed in the medium and the antibodies remained on the cell surface for a long time. In the in vivo studies, the radioantibodies to AFP bound to the AFP-producing cells, especially those producing high levels of AFP (AH66). Tumor localization by scintigraphy was clearer with the AH66 hepatoma than with the AH41C hepatoma, which produces less AFP. The presence of large amounts of AFP in the circulation did not prevent the tumor radioimmunodetection. It is suggested that radioantibodies to AFP bind to the AFP-producing cells despite the presence of large amounts of AFP in the circulation or in ascitic fluid.
已有研究利用产生甲胎蛋白(AFP)的腹水肝癌细胞来阐明放射性标记的抗AFP抗体的定位特性。在体外研究中,即使培养基中存在过量抗原且抗体长时间停留在细胞表面,抗AFP放射性抗体仍会被AFP产生细胞摄取。在体内研究中,抗AFP放射性抗体与AFP产生细胞结合,尤其是那些产生高水平AFP的细胞(AH66)。与产生较少AFP的AH41C肝癌相比,用闪烁扫描法对AH66肝癌进行肿瘤定位更清晰。循环中大量AFP的存在并不妨碍肿瘤的放射免疫检测。这表明,尽管循环或腹水中存在大量AFP,抗AFP放射性抗体仍会与AFP产生细胞结合。